BioFactura's BFI-751, a Biosimilar Ustekinumab, Demonstrates

BioFactura's BFI-751, a Biosimilar Ustekinumab, Demonstrates Pharmacokinetic (PK) Bioequivalence to Stelara® in Phase 1 Study

Frederick, Maryland (PRWEB) October 14, 2022 -- BioFactura Inc. has announced today the completion of the pivotal pharmacokinetic comparability clinical trial

Related Keywords

Australia , New Zealand , Darryl Sampey , Ustekinumab Biosimilar , Jeffreyn Hausfeld , Biofactura Inc , Confidence Interval , Chief Medical Officer , Stablefast Biomanufacturing Platform , Press Release ,